September 18, 2019
InSysBio announces their participation at Tenth American Conference on Pharmacometrics (ACoP10) to be held October 20th to 23rd, 2019, at the Rosen Shingle Creek Hotel in Orlando, FL. The theme of ACoP10 is “Modeling without Borders.”.
Tatiana Karelina, lead modeler in Alzheimer’s Disease, will make an oral presentation “AD pathology QSP platform: studying the interactions between different toxicity modules through the junction of mechanistic submodels” in framework of the concurrent session 2b “QSP modeling in Neuroscience: Novel Technologies and Methodologies” on Monday, 2:00 pm.
InSysBio welcomes visitors at the booth # 11. Also InSysBio team will present twelve posters at the Conference:
Monday, October 21:
- M-066: “Physiologically based pharmacokinetic and receptor occupancy (PBPK/RO) modeling of anti-PD1 monoclonal antibodies” by Oleg Demin Jr and Dmitry Shchelokov
- M-074: “Investigation of bell-shaped dose response of bispecific T-cell engaging antibodies under physiological conditions” by Oleg Demin Jr
- M-087: “Quantitative systems pharmacology model of COPD progression with implemented standard of care treatments (LABA/ ICS)” by Galina Lebedeva, Mikhail Benkov, Oleg Demin, Loveleena Bansal (GSK), Cibele Falkenberg (GSK), Martin Hingle (GSK) and Valeriu Damian (GSK)
Tuesday, October 22:
- T-062: “LikelihoodProfiler Is a Software Package for Practical Identifiability Analysis for the Large-Scale Dynamic Models” by Ivan Borisov and Evgeny Metelkin
- T-075: “Development of quantitative systems pharmacology (QSP) model of systemic lupus erythematosus and its application to explore possible mechanisms of alterations in serum IFN1 resulting from anti-IFNAR1 treatment” by Sergey Smirnov, Alexsandra Diakonova, Oleg Demin, Christopher Morehouse (MedImmune), Dominic Sinibaldi (MedImmune), Raj Tummala (AstraZeneca), Denison Kuruvilla (MedImmune), Yen Len Chia (MedImmune), Lorin K. Roskos (MedImmune) and Wendy I. White (MedImmune)
- T-087: “Influence of neuronal protein degradation pathways on tau pathology studied by Quantitative Systems Pharmacology model” by Tatiana Karelina, Mark Meerson and Diana Klausznitzer (AbbVie)
- T-089: “From stem cell to erythrocyte and platelet: QSP model of erythropoiesis and thrombopoiesis for assessing the impact of pharmacological interventions” by Alexander Stepanov and Galina Lebedeva
- T-094: “Workflow for development of QSP models of Immune Response requires appropriate software infrastructure” by Oleg Demin, Sergey Smirnov, Galina Lebedeva, Oleg Demin Jr, Evgeny Metelkin and Nail Gizzatkulov
- T-099: “’Heta’ is a New Declarative Language to Define the Large-Scale Systems Pharmacology and Systems Biology Models” by Evgeny Metelkin
Wednesday, October 23:
- W-066: “PBPK modeling for therapeutic nanoparticles loaded with drug: distribution and release” by Evgeny Metelkin and Oleg Demin
- W-072: “In vitro to in vivo extrapolation of CD4 T cell polarization in lymph nodes using QSP Modeling” by Oleg Demin, Svetlana Rubina, Dmitry Shchelokov and Oleg Demin Jr
- W-080: “QSP model of human granulopoiesis and neutrophil homeostasis for assessment of pharmacological interventions” by Galina Lebedeva and Alexander Stepanov.
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.